Your browser doesn't support javascript.
loading
Oncolytic Myxoma virus infects and damages the tegument of the human parasitic flatworm Schistosoma mansoni.
Rahman, Masmudur M; McFadden, Grant; Ruthel, Gordon; Herbert, De'Broski R; Freedman, Bruce D; Greenberg, Robert M; Bais, Swarna.
Afiliación
  • Rahman MM; Center for Immunotherapy, Vaccines and Virotherapy, Bio design Institute, Arizona State University, Tempe, AZ, USA.
  • McFadden G; Center for Immunotherapy, Vaccines and Virotherapy, Bio design Institute, Arizona State University, Tempe, AZ, USA.
  • Ruthel G; Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Herbert DR; Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Freedman BD; Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Greenberg RM; Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Bais S; Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: swarnachauhan@gmail.com.
Exp Parasitol ; 239: 108263, 2022 Aug.
Article en En | MEDLINE | ID: mdl-35598646
ABSTRACT
Schistosomiasis is a devastating disease caused by parasitic flatworms of the genus Schistosoma. Praziquantel (PZQ), the current treatment of choice, is ineffective against immature worms and cannot prevent reinfection. The continued reliance on a single drug for treatment increases the risk of the development of PZQ-resistant parasites. Reports of PZQ insusceptibility lends urgency to the need for new therapeutics. Here, we report that Myxoma virus (MYXV), an oncolytic pox virus which is non-pathogenic in all mammals except leporids, infects and replicates in S. mansoni schistosomula, juveniles, and adult male and female worms. MYXV infection results in the shredding of the tegument and reduced egg production in vitro, identifying MYXV as the first viral pathogen of schistosomes. MYXV is currently in preclinical studies to manage multiple human cancers, supporting its use in human therapeutics. Our findings raise the exciting possibility that MYXV virus represents a novel and safe class of potential anthelmintic therapeutics.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Esquistosomiasis mansoni / Virus Oncolíticos / Antihelmínticos / Myxoma virus Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Exp Parasitol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Esquistosomiasis mansoni / Virus Oncolíticos / Antihelmínticos / Myxoma virus Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Exp Parasitol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos